To validate previous observations that plasma level of GDF-15 is a biomarker for poor prognosis in endometrial cancer, plasma level of GDF-15 was determined in an independent patient population including 235 patients with primary endometrial carcinoma. This evidence concerns the gene GDF15 and endometrial carcinoma.